Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Health Insurance > Medicare Planning

CMS Lifts Aetna Medicare Marketing Sanctions

Your article was successfully shared with the contacts you provided.

Aetna Inc. now has permission from the Centers for Medicare and Medicaid Services (CMS) to resume selling Medicare plans.

CMS suspended the ability of Aetna, Hartford (NYSE:AET), to sell new Medicare Advantage and Medicare Part D prescription drug coverage in April 2010 because of concerns about Aetna’s switch to a closed Medicare Part D “formulary,” or covered drugs list, from an open formulary.

Aetna will resume marketing Medicare Advantage and drug plan products immediately, the company says. The company can enroll beneficiaries with effective dates beginning July 1.

Even while the ban on new sales was in place, Aetna has been continuing to provide Medicare Advantage and Medicare drug plan coverage for about 1 million people.

The company provides or administers all types of health coverage for about 18 million people.

- Allison Bell

Other Medicare Advantage coverage from National Underwriter Life & Health:


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.